An Autoimmunity Company

Janus Biotherapeutics is an autoimmunity therapeutics company dedicated to the development of novel, orally available compounds for the treatment of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, psoriasis, and scleroderma.

NEWS: Janus Biotherapeutics enters collaboration with Roche in autoimmune diseases for the development of a small molecule toll-like receptor (TLR) inhibitor.


Approximately 46 million people in the United States suffer from autoimmune rheumatic diseases, a number that is expected to reach 60 million by 2020. These conditions exact a significant toll on the physical health, emotional well-being.

More Info


Realization of the importance of abnormal TLR activation and dendritic cell dysregulation in the development of autoimmune diseases opens up the possibility of an exciting new approach for the treatment of patients with certain of these disorders.

More Info

About Us

Janus Bio is exploring exciting new approaches for the treatment of autoimmune rheumatic diseases. We are comprised of an active management team, a board of directors, and scientific advisors. Janus is also partners with Roche Pharmaceuticals.

More Info